ImmunityBio Shares Surge on Promising Lung Cancer Trial Data

ImmunityBio’s stock experienced a significant boost, climbing more than 8%, following the presentation of compelling new data from its Phase 2 clinical trial, QUILT-3.055. The data, unveiled at the World Conference on Lung Cancer, demonstrated that the company’s drug candidate, ANKTIVA, provided substantial survival benefits for patients with advanced non-small cell lung cancer who had ceased responding to conventional immunotherapy treatments.

This development introduces a potential turning point for the biotech firm, which has seen its share price decline more than 60% from its annual peak. The positive results could signal a reversal of fortune, pulling the equity out of its downward trend.

A Novel Mechanism Driving Investor Enthusiasm

The investor excitement stems from ANKTIVA’s unique mechanism of action. The therapy is the first of its kind shown to successfully reverse cancer-related lymphopenia—a deficiency of immune cells in the blood that is frequently associated with poor treatment outcomes. According to the trial results, this reversal directly correlated with markedly extended survival times for the study’s participants.

This breakthrough positions ImmunityBio in the highly lucrative oncology market with a fresh narrative. The positive data arrive at a crucial time, helping to counterbalance recent regulatory challenges. The company had previously faced investor uncertainty after receiving a Complete Response Letter from the U.S. FDA in May 2025 for a supplemental Biologics License Application (sBLA) related to ANKTIVA’s use in bladder cancer.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Targeting a Substantial Market Opportunity

While ANKTIVA is already approved for certain types of bladder cancer, a successful expansion into lung cancer treatment would open access to a vastly larger commercial opportunity. The lung cancer market represents a multi-billion dollar frontier, and a successful entry could fundamentally alter ImmunityBio’s growth trajectory.

The company’s strategic focus is now on advancing its lung cancer program. Market observers will be watching for forthcoming details on the regulatory pathway and timeline for this potential new application.

Next Milestones: Commercial Execution and Future Data

The immediate focus for investors shifts to the company’s upcoming quarterly report, scheduled for release in November. This earnings release will provide critical insight into the early commercial performance of ANKTIVA for its approved bladder cancer indication.

Simultaneously, the market will await further updates on the development plan for the lung cancer program. Should the encouraging trial results be confirmed in subsequent studies, ImmunityBio may have unlocked a transformative new revenue stream, suggesting its recent stock performance may represent a temporary setback rather than a long-term decline.